王凡教授的技术成果《新型特异性肿瘤显像剂》以3000万元签约资金成功进行成果转化。还获得了国家授权发明专利5项。

目前放射医学系承担部级以上科研项目20余项，承担863，973，科技部重大专项，国家自然科学基金国际合作，面上项目，以及“杰青”和“优青”等人才培养项目，总经费超过2000万元。项目如下：

1、北大百人100万元2015-2017

2、自然科学基金面上项目75万元2015-2018

3、国家自然科学基金委重点国际合作研究项目300万

4、北京市科技计划项目200万

5、科技部"重大新药创制"重大专项450万

6、国家杰出青年科学基金240万

7、国家自然科学基金委重点项目185万

8、科技部"863"项目 300万

9、国家自然科学基金委面上项目（81471712）73 万

10、国家自然科学基金委优秀青年科学基金（81222019）100万

11、北京市“科技新星计划”课题（Z121107002512010）28万

12、北京市自然科学基金（7132131）14万

13、国家自然科学基金委青年基金（81000625）21万

放射医学系过去三年中在影响因子大于5的邻域权威杂志中发表10余篇高水平论文，其中王嘉东以北京大学医学部放射医学教研室为第一单位在Genes & Development(IF:12.951)杂志上发表论文，“优青”刘昭飞在Biomaterials（IF:8.557）杂志上发表论文。2015年，放射医学系文章发表平均影响因子在基础医学院各院系处前列。各PI所发代表性论文（*通讯作者）如下：

（一）王嘉东：

1. Wang J, Aroumougame A, Lobrich M, Li Y, Chen D, Chen J, Gong Z PTIP associates with Artemis to dictate DNA repair pathway choice Gene Dev 2014

2. Wang J, Gong Z, Chen J. TopBP1 Controls BLM Protein Level to Suppress Sister Chromatid Exchange. Mol Cell 52 (2013), 667-678.

3. Wang J, Leung JW, Gong Z, Feng L, Shi X, Chen J. PHF6 regulates cell cycle progression by suppressing ribosomal RNA synthesis. J Biol Chem. 288(5):3174-83 2013 PMID: 23229552

4. Wang J, Gong Z, Chen J. Chen MDC1 collaborates with TopBP1 in DNA replication checkpoint control. J Cell Biol. 193(2):267-73 2011 PMID: 21482717

5. Liu N, Wang J (co-first), Wang J, Wang R, Liu Z, Yu Y, Lu H. ING5 Is a Tip60 Cofactor That Acetylates p53 in Response to DNA Damage. Cancer Res. 73(12):3749-60 2013 PMID: 23576563

6. Feng L, Fong KW, Wang J, Wang W, Chen J.RIF1 counteracts BRCA1-mediated end resection during DNA repair. J Biol Chem. 288(16):11135-43. 2013 Mar PMID: 23486525

7. Feng L, Wang J, Chen J. The Lys63-specific deubiquitinating enzyme BRCC36 is regulated by two scaffold proteins localizing in different subcellular compartments.J Biol Chem. 285(40):30982-8 2010 PMID: 20656690

8. Wang J, Chen J.SIRT1 regulates autoacetylation and histone acetyltransferase activity of TIP60 J Biol Chem.285(15):11458-64.  04/2010.  PMCID: PMC2857024

       

      （二）王凡：

1. Yu X, Wu Y, Liu H, Gao L, Sun X, Zhang C, Shi J, Zhao H, Jia B, Liu Z, Wang F*. Small-animal SPECT/CT of the progression and recovery of rat liver fibrosis by using an integrin αvβ3-targeting radiotracer. Radiology. 2016, 279(2):502-12.

2. Liu Z*, Liu H, Ma T, Sun X, Shi J, Jia B, Sun Y, Zhan J, Zhang H, Zhu Z, Wang F*. Integrin αvβ6-targeted SPECT imaging for pancreatic cancer detection. J Nucl Med. 2014, 55(6):989-994.

3. Liu Z*, Sun X, Liu H, Ma T, Shi J, Jia B, Zhao H, Wang F*. Early Assessment of Tumor Response to Gefitinib Treatment by Noninvasive Optical Imaging of Tumor Vascular Endothelial Growth Factor Expression in Animal Models. J Nucl Med. 2014, 55(5):818-23.

4. Liu Z*, Ma T, Liu H, Jin Z, Sun X, Zhao H, Shi J, Jia B, Li F, Wang F*. ¹⁷⁷Lu-Labeled Antibodies for EGFR-Targeted SPECT/CT Imaging and Radioimmunotherapy in a Preclinical Head and Neck Carcinoma Model. Mol Pharmaceut. 2014, 11:800？807.

5. Shi J, Fan D, Dong C, Liu H, Jia B, Zhao H, Jin X, Liu Z, Li F, Wang F*. Anti-tumor Effect of Integrin Targeted 177Lu-3PRGD2 and Combined Therapy with Endostar. Theranostics. 2014, 4(3):256-266.

6. Dong C, Zhao H, Yang S, Shi J, Huang J, Cui L, Zhong L, Jin X, Li F, Liu Z, Jia B*, Wang F*. ^99mTc-Labeled Dimeric Octreotide Peptide: a Radiotracer with High Tumor Uptake for Single-Photon Emission Computed Tomography Imaging of Somatostatin Receptor Subtype2-positive Tumors. Mol Pharmaceut. 2013, 10(8):2925-2933.

7. Liu Z*, Huang J, Dong C, Cui L, Jin X, Jia B, Zhu Z, Li F, Wang F*. ^99mTc-Labeled RGD-BBN Peptide for Small-Animal SPECT/CT of Lung Carcinoma. Mol Pharmaceut. 2012, 9(5):1409-1417.

8. Zhu Z, Weibing Miao W, Li Q, Dai H, Ma Q, Wang F, Yang A, Jia B, Jing X, Sha L, Shi J, Liu Z, Zhao Z, Wang F*, Li F*. 99mTc-3PRGD2 for Integrin Receptor Imaging of Lung Cancer: a Multi-Center Study. J Nucl Med. 2012, 53(5):716-722.

9. Liu Z, Shi J, Jia B*, Yu Z, Liu Y, Zhao H, Li F, Tian J, Chen X, Liu S, Wang F*. Two ⁹⁰Y-Labeled Multimeric RGD Peptides RGD4 and 3PRGD2 for Integrin Targeted Radionuclide Therapy. Mol Pharmaceut. 2011, 8(2):591-599.

10. Liu Z, Liu Y, Jia B, Zhao H, Jin X, Li F, Chen X, Wang F*. Epidermal Growth Factor Receptor–Targeted Radioimmunotherapy of Human Head and Neck Cancer Xenografts Using 90Y-Labeled Fully Human Antibody Panitumumab. Mol Cancer Ther. 2010, 9(8):2297-2308.

（三）刘昭飞：

1. Gao L, Zhang C, Gao D, Liu H, Yu X, Lai J, Wang F, Lin J, Liu Z*. Enhanced anti-tumor efficacy through combination integrin αvβ6-targeted photodynamic therapy and immune checkpoint inhibition. Theranostics. 2016, 6:627-637.

2. Zhang C, Gao L, Cai Y, Liu H, Gao D, Lai J, Jia B, Wang F, Liu Z*. Inhibition of tumor growth and metastasis by photoimmunotherapy targeting tumor-associated macrophage in a sorafenib-resistant tumor model. Biomaterials. 2016, 84:1-12.

3. Gao L, Liu H, Sun X, Gao D, Zhang C, Jia B, Zhu Z, Wang F, Liu Z*. Molecular imaging of post-Src-inhibition tumor signatures for guiding dasatinib combination therapy. J Nucl Med. 2016, 57:321-326.(同期配发评论该研究的Invited Perspectives, 见J Nucl Med. 2016, 57:171-172)

4. Gao D, Gao L, Zhang C, Liu H, Jia B, Zhu Z, Wang F, Liu Z*. A near-infrared phthalocyanine dye-labeled agent for integrin αvβ6-targeted theranostics of pancreatic cancer. Biomaterials. 2015, 53:229-238.

5. Sun X, Gao D, Gao L, Zhang C, Yu X, Jia B, Wang F, Liu Z*. Molecular imaging of tumor-infiltrating macrophages in a preclinical mouse model of breast cancer. Theranostics. 2015, 5:597-608.

6. Ma T, Sun X, Cui L, Gao L, Wu Y, Liu H, Zhu Z, Wang F, Liu Z*. Molecular imaging reveals trastuzumab-induced epidermal growth factor receptor downregulation in vivo. J Nucl Med. 2014, 55:1002-1007.

7. Sun X, Ma T, Liu H, Yu X, Wu Y, Shi J, Jia B, Zhao H, Wang F*, Liu Z*. Longitudinal monitoring of tumor antiangiogenic therapy with near-infrared fluorophore-labeled agents targeted to integrin α_vβ₃ and vascular endothelial growth factor. Eur J Nucl Med Mol Imaging. 2014, 41:1428-39.

8. Liu Z*, Liu H, Ma T, Sun X, Shi J, Jia B, Sun Y, Zhan J, Zhang H, Zhu Z, Wang F*. Integrin α_vβ₆-targeted SPECT imaging for pancreatic cancer detection. J Nucl Med. 2014,55:989-994.

9. Liu Z*, Sun X, Liu H, Ma T, Shi J, Jia B, Zhao H, Wang F*. Early assessment of tumor response to gefitinib treatment by noninvasive optical imaging of tumor vascular endothelial growth factor expression in animal models. J Nucl Med. 2014, 55:818-823.